Instrument Inactif

Autres langues Cellmid Limited Australian S.E.

Actions

CDYDA

AU0000CDYDA5

Produits cosmétiques

Autres langues

28/08	Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2026
01/03	Anagenics Limited Announces Appointment of Josh Gordon as Non-Executive Director
24/02	Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2025
29/01	Anagenics Limited Announces Change of Address
10/12	Anagenics to raise A$2.25 mln at A$0.0046 per share
08/12	Anagenics requests trading halt
28/08/25	Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2025
27/06/25	Anagenics' Bouf Haircare Surpasses Expectations, Poised for Strong First-Year Growth; Shares Up 25%
05/05/25	Anagenics' Revenue in Fiscal Q3 Falls After Restructure
27/02/25	Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2024
04/02/25	Anagenics Says Dialogue with Roquefort Ongoing Regarding Lyramid Divestment
13/01/25	Anagenics Expects ASX Relisting Process to Be Completed by End of February
05/01/25	Anagenics Continues Talks With ASX to Lift Trading Suspension
31/10/24	Anagenics Limited Announces Resignation of Karen Matthews as Director
16/10/24	Matthew Perry, Sarah Jane Perry, and entities they control completed the acquisition of Face Medigroup Retail Pty Ltd from Anagenics Limited.
08/10/24	Anagenics Limited Announces Retirement of Karen Mathews as Chief Executive Officer
03/10/24	Anagenics : 2024 Anagenics Annual Report
02/10/24	Matthew Perry, Sarah Jane Perry, and entities they control agreed to acquire Face Medigroup Retail Pty Ltd from Anagenics Limited.
30/08/24	Anagenics Limited Reports Earnings Results for the Full Year Ended June 30, 2024
25/07/24	Anagenics Posts 16% Jump in FY 2024 Revenue, Secures Licensing Partnership
24/05/24	Anagenics Signs Midkine Antibody Licencing Deal with Roquefort Therapeutics
08/03/24	Anagenics Appoints CEO
26/02/24	Anagenics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
07/02/24	Anagenics Completes Placement to Raise AU$1.3 Million
31/01/24	Anagenics Grows Fiscal H1 Revenue